Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where

Papers of special note have been highlighted as: ▪▪ of considerable interest

References

• 1  Citron M. Alzheimer’s disease: strategies for disease modification. Nat. Rev. Drug Discov.9(5),387–398 (2010).
  Medline CASGoogle Scholar
• 2  Wenk GL. Neuropathologic changes in Alzheimer’s disease. J. Clin. Psychiatry64(Suppl. 9),7–10 (2003).
  MedlineGoogle Scholar
• 3  Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem.283(44),29615–29619 (2008).
  Medline CASGoogle Scholar
• 4  Mohamed A, Cortez L, de Chaves EP. Aggregation state and neurotoxic properties of alzheimer β-amyloid peptide. Curr. Protein. Pept. Sci.12(3),235–257 (2011).
  Medline CASGoogle Scholar
• 5  Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer’s disease. Mt Sinai J. Med.77(1),69–81 (2010).
  MedlineGoogle Scholar
• 6  Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature416(6880),535–539 (2002).
  Medline CASGoogle Scholar
• 7  Shankar GM, Li S, Mehta TH et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med.14(8),837–842 (2008).
  Medline CASGoogle Scholar
• 8  Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH. Alzheimer’s disease. A double-labeling immunohistochemical study of senile plaques. Am. J. Pathol.132(1),86–101 (1988).
  Medline CASGoogle Scholar
• 9  Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol.77(6),569–575 (1989).
  Medline CASGoogle Scholar
• 10  Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol.24(3),173–182 (1989).
  Medline CASGoogle Scholar
• 11  el Hachimi KH, Foncin JF. Do microglial cells phagocyte the beta/A4-amyloid senile plaque core of Alzheimer disease? C. R. Acad. Sci. III317(5),445–451 (1994).
  Medline CASGoogle Scholar
• 12  Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol.11(11),723–737 (2011).
  Medline CASGoogle Scholar
• 13  Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol.27,119–145 (2009).
  Medline CASGoogle Scholar
• 14  Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol.75(3),388–397 (2004).▪▪ Detailed review on the phenotypic markers used to differentiate various macrophage subsets.
  Medline CASGoogle Scholar
• 15  Dalkara T, Gursoy-Ozdemir Y, Yemisci M. Brain microvascular pericytes in health and disease. Acta Neuropathol.122(1),1–9 (2011).
  MedlineGoogle Scholar
• 16  Sedgwick JD, Schwender S, Imrich H, Dörries R, Butcher GW, ter Meulen V. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl Acad. Sci. USA88(16),7438–7442 (1994).
  Google Scholar
• 17  Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci.10(11),1387–1394 (2004).
  Google Scholar
• 18  de Haas AH, Boddeke HW, Biber K. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia56(8),888–894 (2008).
  MedlineGoogle Scholar
• 19  McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging28(5),639–647 (2007).
  Medline CASGoogle Scholar
• 20  Breitner JC, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology44(2),227–232 (1994).
  Medline CASGoogle Scholar
• 21  Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol.57(2–3),239–242 (1982).
  Medline CASGoogle Scholar
• 22  Eikelenboom P, Stam FC. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer’s dementia. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol.47(1),17–25 (1984).
  Medline CASGoogle Scholar
• 23  Ishii T, Haga S. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol.63(4),296–300 (1984).
  Medline CASGoogle Scholar
• 24  Wisniewski HM, Barcikowska M, Kida E. Phagocytosis of beta/A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropathol.81(5),588–590 (1991).
  Medline CASGoogle Scholar
• 25  Wisniewski HM, Wegiel J, Wang KC, Kujawa M, Lach B. Ultrastructural studies of the cells forming amyloid fibers in classical plaques. Can. J. Neurol. Sci.16(4 Suppl.),535–542 (1989).▪▪ Seminal paper providing the first evidence for differential clearance of amyloid-β peptides (Aβ) by microglia and infiltrating macrophages.
  Medline CASGoogle Scholar
• 26  Wisniewski HM, Vorbrodt AW, Wegiel J, Morys J, Lossinsky AS. Ultrastructure of the cells forming amyloid fibers in Alzheimer disease and scrapie. Am. J. Med. Genet. Suppl.7,287–297 (1990).
  Medline CASGoogle Scholar
• 27  Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol.84(3),225–233 (1992).
  Medline CASGoogle Scholar
• 28  Akiyama H, Kondo H, Mori H et al. The amino-terminally truncated forms of amyloid beta-protein in brain macrophages in the ischemic lesions of Alzheimer’s disease patients. Neurosci. Lett.219(2),115–118 (1996).
  Medline CASGoogle Scholar
• 29  Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am. J. Pathol.154(6),1673–1684 (1999).
  Medline CASGoogle Scholar
• 30  Stalder M, Deller T, Staufenbiel M, Jucker M. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging22(3),427–434 (2001).
  Medline CASGoogle Scholar
• 31  Avagyan H, Goldenson B, Tse E et al. Immune blood biomarkers of Alzheimer disease patients. J. Neuroimmunol.210(1–2),67–72 (2009).
  Medline CASGoogle Scholar
• 32  Zaghi J, Goldenson B, Inayathullah M et al. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol.117(2),111–124 (2009).
  Medline CASGoogle Scholar
• 33  Fiala M, Liu PT, Espinosa-Jeffrey A et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer’s disease patients are improved by bisdemethoxycurcumin. Proc. Natl Acad. Sci. USA104(31),12849–12854 (2007).
  Medline CASGoogle Scholar
• 34  Masoumi A, Goldenson B, Ghirmai S et al. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. J. Alzheimers. Dis.17(3),703–717 (2009).
  Medline CASGoogle Scholar
• 35  Familian A, Eikelenboom P, Veerhuis R. Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci. Lett.416(1),87–91 (2007).
  Medline CASGoogle Scholar
• 36  Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer’s disease amyloid beta-protein by microglial cells. J. Biol. Chem.272(46),29390–29397 (1997).
  Medline CASGoogle Scholar
• 37  Chung H, Brazil MI, Soe TT, Maxfield FR. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer’s amyloid beta-peptide by microglial cells. J. Biol. Chem.274(45),32301–32308 (1999).
  Medline CASGoogle Scholar
• 38  Majumdar A, Chung H, Dolios G et al. Degradation of fibrillar forms of Alzheimer’s amyloid beta-peptide by macrophages. Neurobiol. Aging29(5),707–715 (2008).
  Medline CASGoogle Scholar
• 39  Mitrasinovic OM, Murphy GM Jr. Accelerated phagocytosis of amyloid-beta by mouse and human microglia overexpressing the macrophage colony-stimulating factor receptor. J. Biol. Chem.277(33),29889–29896 (2002).
  Medline CASGoogle Scholar
• 40  Mitrasinovic OM, Vincent VA, Simsek D, Murphy GM Jr. Macrophage colony stimulating factor promotes phagocytosis by murine microglia. Neurosci. Lett.344(3),185–188 (2003).
  Medline CASGoogle Scholar
• 41  Mitrasinovic OM, Murphy GM Jr. Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta. Neurobiol. Aging24(6),807–815 (2003).
  Medline CASGoogle Scholar
• 42  Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol.7(2),161–167 (2007).
  Medline CASGoogle Scholar
• 43  Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer’s disease. Brain132(Pt 4),1078–1092 (2009).
  MedlineGoogle Scholar
• 44  Sanchez-Ramos J, Song S, Sava V et al. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer’s mice. Neuroscience163(1),55–72 (2009).
  Medline CASGoogle Scholar
• 45  Boyd TD, Bennett SP, Mori T et al. GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J. Alzheimers Dis.21(2),507–518 (2010).
  Medline CASGoogle Scholar
• 46  Herber DL, Roth LM, Wilson D et al. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp. Neurol.190(1),245–253 (2004).
  Medline CASGoogle Scholar
• 47  Herber DL, Mercer M, Roth LM et al. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J. Neuroimmune Pharmacol.2(2),222–231 (2007).
  MedlineGoogle Scholar
• 48  Qiao X, Cummins DJ, Paul SM. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci.14(3),474–482 (2001).
  Medline CASGoogle Scholar
• 49  Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740),173–177 (1999).
  Medline CASGoogle Scholar
• 50  Morgan D. Immunotherapy for Alzheimer’s disease. J. Intern. Med.269(1),54–63 (2011).
  Medline CASGoogle Scholar
• 51  Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease. Peptides23(12),2223–2226 (2002).
  Medline CASGoogle Scholar
• 52  Farrall AJ, Wardlaw JM. Blood–brain barrier: ageing and microvascular disease – systematic review and meta-analysis. Neurobiol. Aging30(3),337–352 (2009).
  Medline CASGoogle Scholar
• 53  Ujiie M, Dickstein DL, Carlow DA, Jefferies WA. Blood–brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation10(6),463–470 (2003).
  Medline CASGoogle Scholar
• 54  Kumar-Singh S, Pirici D, McGowan E et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer’s disease are centered on vessel walls. Am. J. Pathol.167(2),527–543 (2005).
  Medline CASGoogle Scholar
• 55  Dickstein DL, Biron KE, Ujiie M, Pfeifer CG, Jeffries AR, Jefferies WA. Abeta peptide immunization restores blood–brain barrier integrity in Alzheimer disease. FASEB J.20(3),426–433 (2006).
  Medline CASGoogle Scholar
• 56  Biron KE, Dickstein DL, Gopaul R, Jefferies WA. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer‘s disease. PLoS ONE6(8),e23789 (2011).
  Medline CASGoogle Scholar
• 57  Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med.6(8),916–919 (2000).
  Medline CASGoogle Scholar
• 58  Wilcock DM, Rojiani A, Rosenthal A et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci.24(27),6144–6151 (2004).
  Medline CASGoogle Scholar
• 59  Zhang L, Fiala M, Cashman J et al. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patients. J. Alzheimers Dis.10(1),1–7 (2006).
  MedlineGoogle Scholar
• 60  Yanagisawa D, Shirai N, Amatsubo T et al. Relationship between the tautomeric structures of curcumin derivatives and their Abeta-binding activities in the context of therapies for Alzheimer’s disease. Biomaterials31(14),4179–4185 (2010).
  Medline CASGoogle Scholar
• 61  Hawkes CA, Deng L, Fenili D, Nitz M, McLaurin J. In vivo uptake of beta-amyloid by non-plaque associated microglia. Curr. Alzheimer Res. (2011) (Epub ahead of print).
  Google Scholar
• 62  Heppner FL, Greter M, Marino D et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med.11(2),146–152 (2005).
  Medline CASGoogle Scholar
• 63  Gowing G, Vallières L, Julien JP. Mouse model for ablation of proliferating microglia in acute CNS injuries. Glia53(3),331–337 (2006).
  MedlineGoogle Scholar
• 64  Grathwohl SA, Kälin RE, Bolmont T et al. Formation and maintenance of Alzheimer’s disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci.12(11),1361–1363 (2009).▪▪ Unique experimental model where resident microglia are selectively ablated; provides support for their role as bystanders in Aβ clearance.
  Medline CASGoogle Scholar
• 65  Rezai-Zadeh K, Gate D, Gowing G, Town T. How to get from here to there: macrophage recruitment in Alzheimer’s disease. Curr. Alzheimer Res.8(2),156–163 (2011).
  Medline CASGoogle Scholar
• 66  Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm.117(8),949–960 (2010).
  Medline CASGoogle Scholar
• 67  Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer’s disease. Neuron49(4),489–502 (2006).
  Medline CASGoogle Scholar
• 68  Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science239(4837),290–292 (1988).
  Medline CASGoogle Scholar
• 69  Malm TM, Koistinaho M, Pärepalo M et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol. Dis.18(1),134–142 (2005).
  Medline CASGoogle Scholar
• 70  Stalder AK, Ermini F, Bondolfi L et al. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci.25(48),11125–11132 (2005).
  Medline CASGoogle Scholar
• 71  Mildner A, Schmidt H, Nitsche M et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat. Neurosci.10(12),1544–1553 (2007).
  Medline CASGoogle Scholar
• 72  Mildner A, Schlevogt B, Kierdorf K et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer’s disease. J. Neurosci.31(31),11159–11171 (2011).▪▪ Pivotal paper demonstrating the importance of various populations of myeloid cells in clearing parenchymal Aβ examined within the same experimental paradigm.
  Medline CASGoogle Scholar
• 73  Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci.10(12),1538–1543 (2007).
  Medline CASGoogle Scholar
• 74  Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood–brain barrier in rabbits. Radiology220(3),640–646 (2001).
  Medline CASGoogle Scholar
• 75  Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood–brain barrier disruption. Proc. Natl Acad. Sci. USA103(31),11719–11723 (2006).
  Medline CASGoogle Scholar
• 76  Jordão JF, Ayala-Grosso CA, Markham K et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer’s disease. PLoS ONE5(5),e10549 (2010).
  MedlineGoogle Scholar
• 77  Burgess A, Ayala-Grosso CA, Ganguly M, Jordão JF, Aubert I, Hynynen K. Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood–brain barrier. PLoS ONE6(11),e27877 (2011).
  Medline CASGoogle Scholar
• 78  Ueno M, Nakagawa T, Wu B et al. Transporters in the brain endothelial barrier. Curr. Med. Chem.17(12),1125–1138 (2010).
  Medline CASGoogle Scholar
• 79  Attems J, Jellinger K, Thal DR, van Nostrand W. Review: sporadic cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol.37(1),75–93 (2011).
  Medline CASGoogle Scholar
• 80  Hawkes CA, McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl Acad. Sci. USA106(4),1261–1266 (2009).
  Medline CASGoogle Scholar
• 81  Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res.29(6),313–326 (2009).
  Medline CASGoogle Scholar
• 82  Naert G, Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer’s disease. J. Neurosci.31(16),6208–6220 (2011).
  Medline CASGoogle Scholar
• 83  El Khoury J, Toft M, Hickman SE et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med.13(4),432–438 (2007).
  Medline CASGoogle Scholar
• 84  Yamamoto M, Horiba M, Buescher JL et al. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am. J. Pathol.166(5),1475–1485 (2005).
  Medline CASGoogle Scholar
• 85  Kiyota T, Yamamoto M, Xiong H et al. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE4(7),e6197 (2009).
  MedlineGoogle Scholar
• 86  Lee S, Varvel NH, Konerth ME et al. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer’s disease mouse models. Am. J. Pathol.177(5),2549–2562 (2010).
  Medline CASGoogle Scholar
• 87  Liu Z, Condello C, Schain A, Harb R, Grutzendler J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis. J. Neurosci.30(50),17091–17101 (2010).
  Medline CASGoogle Scholar
• 88  Fuhrmann M, Bittner T, Jung CK et al. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer‘s disease. Nat. Neurosci.13(4),411–413 (2010).
  Medline CASGoogle Scholar
• 89  Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci.28(25),6333–6341 (2008).
  Medline CASGoogle Scholar
• 90  Wyss-Coray T, Yan F, Lin AH et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc. Natl Acad. Sci. USA99(16),10837–10842 (2002).
  Medline CASGoogle Scholar
• 91  Huang SM, Mouri A, Kokubo H et al. Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J. Biol. Chem.281(26),17941–17951 (2006).
  Medline CASGoogle Scholar
• 92  Madani R, Poirier R, Wolfer DP et al. Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. J. Neurosci. Res.84(8),1871–1878 (2006).
  Medline CASGoogle Scholar
• 93  Farris W, Schütz SG, Cirrito JR et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol.171(1),241–251 (2007).
  Medline CASGoogle Scholar
• 94  Marr RA, Rockenstein E, Mukherjee A et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci.23(6),1992–1996 (2003).
  Medline CASGoogle Scholar
• 95  Iwata N, Mizukami H, Shirotani K et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J. Neurosci.24(4),991–998 (2004).
  Medline CASGoogle Scholar
• 96  Miners JS, Barua N, Kehoe PG, Gill S, Love S. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol.70(11),944–959 (2011).
  Medline CASGoogle Scholar
• 97  Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J. Neurosci.28(33),8354–8360 (2008).▪▪ Demonstrates loss of several aspects of Aβ-degrading capabilities in microglia as a function of age.
  Medline CASGoogle Scholar
• 98  Mohamed A, Posse de Chaves E. Aβ internalization by neurons and glia. Int. J. Alzheimers Dis.2011,127984 (2011).
  MedlineGoogle Scholar
• 99  Huang F, Buttini M, Wyss-Coray T et al. Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. Am. J. Pathol.155(5),1741–1747 (1999).
  Medline CASGoogle Scholar
• 100  Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S. Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc. Natl Acad. Sci. USA107(48),20816–20821 (2010).
  Medline CASGoogle Scholar
• 101  Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of Toll-like receptor signalling in Abeta uptake and clearance. Brain129(Pt 11),3006–3019 (2006).
  MedlineGoogle Scholar
• 102  Song M, Jin J, Lim JE et al. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J. Neuroinflammation8,92 (2011).
  Medline CASGoogle Scholar
• 103  Richard KL, Filali M, Préfontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1–42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. J. Neurosci.28(22),5784–5793 (2008).
  Medline CASGoogle Scholar
• 104  Michaud JP, Richard KL, Rivest S. MyD88-adaptor protein acts as a preventive mechanism for memory deficits in a mouse model of Alzheimer’s disease. Mol. Neurodegener.6(1),5 (2011).
  Medline CASGoogle Scholar
• 105  Lim JE, Kou J, Song M et al. MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease. Am. J. Pathol.179(3),1095–1103 (2011).
  Medline CASGoogle Scholar
• 106  Tan J, Town T, Mori T et al. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J. Neurosci.20(20),7587–7594 (2000).
  Medline CASGoogle Scholar
• 107  Townsend KP, Vendrame M, Ehrhart J et al. CD45 isoform RB as a molecular target to oppose lipopolysaccharide-induced microglial activation in mice. Neurosci. Lett.362(1),26–30 (2004).
  Medline CASGoogle Scholar
• 108  Zhu Y, Hou H, Rezai-Zadeh K et al. CD45 deficiency drives amyloid-peptide oligomers and neuronal loss in Alzheimer’s disease mice. J. Neurosci.31(4),1355–1365 (2011).
  Medline CASGoogle Scholar
• 109  Townsend KP, Town T, Mori T et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur. J. Immunol.35(3),901–910 (2005).
  Medline CASGoogle Scholar
• 110  Tan J, Town T, Paris D et al. Microglial activation resulting from CD40–CD40L interaction after beta-amyloid stimulation. Science286(5448),2352–2355 (1999).
  Medline CASGoogle Scholar
• 111  Tan J, Town T, Crawford F et al. Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice. Nat. Neurosci.5(12),1288–1293 (2002).
  Medline CASGoogle Scholar
• 112  Keene CD, Chang RC, Lopez-Yglesias AH et al. Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer’s disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am. J. Pathol.177(1),346–354 (2010).▪▪ In vivo manipulation of microglia/macrophages into an anti-inflammatory pro-Aβ-clearing phenotype.
  Medline CASGoogle Scholar
• 113  Shie FS, Breyer RM, Montine TJ. Microglia lacking E Prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am. J. Pathol.166(4),1163–1172 (2005).
  Medline CASGoogle Scholar
• 114  Town T, Laouar Y, Pittenger C et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med.14(6),681–687 (2008).▪▪ In vivo manipulation of microglia/macrophages into an anti-inflammatory pro-Aβ-clearing phenotype.
  Medline CASGoogle Scholar
• 115  Salins P, He Y, Olson K, Glazner G, Kashour T, Amara F. TGF-beta1 is increased in a transgenic mouse model of familial Alzheimer’s disease and causes neuronal apoptosis. Neurosci. Lett.430(1),81–86 (2008).
  Medline CASGoogle Scholar
• 116  Wyss-Coray T, Lin C, Yan F et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med.7(5),612–618 (2001).
  Medline CASGoogle Scholar
• 117  Streit WJ, Sammons NW, Kuhns AJ, Sparks DL. Dystrophic microglia in the aging human brain. Glia45(2),208–212 (2004).
  MedlineGoogle Scholar
• 118  Lopes KO, Sparks DL, Streit WJ. Microglial dystrophy in the aged and Alzheimer’s disease brain is associated with ferritin immunoreactivity. Glia56(10),1048–1060 (2008).
  MedlineGoogle Scholar
• 119  Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol.118(4),475–485 (2009).
  MedlineGoogle Scholar
• 120  Szekely CA, Thorne JE, Zandi PP et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology23(4),159–169 (2004).
  MedlineGoogle Scholar
• 121  Streit WJ. Microglial senescence: does the brain’s immune system have an expiration date? Trends Neurosci.29(9),506–510 (2006).
  Medline CASGoogle Scholar
• 122  Flanary BE, Streit WJ. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia45(1),75–88 (2004).
  MedlineGoogle Scholar
• 123  Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol. Aging33(1),195.e1–12 (2010).
  Google Scholar
• 124  Rolyan H, Scheffold A, Heinrich A et al. Telomere shortening reduces Alzheimer’s disease amyloid pathology in mice. Brain134(Pt 7),2044–2056 (2011).
  MedlineGoogle Scholar
• 201  Clinical Trials Database. http://clinicaltrials.gov/ct2/show/nct01473485?term=ultrasound+mri+brain+tumor&rank=2
  Google Scholar